A study on hemophilia A & B patients in Moldova and Georgia being sponsored by ApcinteX recently posted results about its Phase 2a trails.
Quick Results: The experimental drug being developed by ApcinteX is called SerpinPC. In its Phase 2a trails, it was administered to hemophilia A and B patients. SerpinPC when administered at a high dose reduced overall bleed rates in adults by up to 88 percent and spontaneous joint bleeds by up to 94 percent.
Detailed Results: The experimental drug being developed by ApcinteX is called SerpinPC. In its Phase 2a trails, it was administered to hemophilia A and B patients. SerpinPC when administered at a high dose reduced overall bleed rates in adults by up to 88 percent and spontaneous joint bleeds by up to 94 percent. SerpinPC is a subcutaneous injection and according to Hemophilia News Today, has the possibility to treat every type of hemophilia, regardless of its severity. Antoine Yver, MD, who is the chief medical officer of Centessa Pharmaceuticals (ApcinteX) says, "we are eager to move SerpinPC into a global development plan."
Phase 2a involved and evaluated the results of 23 male patients who were not treating prophylactic for hemophilia. None of the 23 men evaluated had inhibitors. The annualized bleed rate of the patients was compared to prior annualized bleed rates, taken before SerpinPC injection.
There were three dose groups, and different dose groups responded differently.
The 0.3 mg/kg dose group self-reported a median annualized bleed rate reduction for all types of bleeds by 80 percent.
The 0.6 mg/kg dose group reported a median annualized bleed rate reduction for all bleeds by 70 percent. Spontaneous joint bleeds also decreased by 69 percent.
The 1.2 mg/kg dose group, reported a median annualized bleed rate reduction of all bleeds by 88 percent. Spontaneous joint bleeds decreased by 94 percent.
Out of the 8 patients in the high dosage group (1.2 mg/kg), 5 of them reported one or fewer (zero) bleeds over the 12-week assessment period.
Comentarios